Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Organisation › Details

Pieris Pharmaceuticals Inc. (Nasdaq: PIRS)

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin® protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. *


Period Start 2014-12-17 merged
  Group Pieris (Group)
  Predecessor Marika Inc.
Products Industry BIOTECH
  Industry 2 Anticalin® scaffold technology
Persons Person Yoder, Stephen S. (Steve) (Pieris 201001– CEO before MorphoSys Head Licensing + IP)
  Person 2 Deptula-Hicks, Darlene (Pieris 201509–201702 CFO before consultant to Pieris RESIGNED 2/17)
Region Region Boston, MA
  Country United States (USA)
  Street 255 State Street
9th Floor
  City 85354 Boston, MA
  Tel +1-857-246-8998
    Address record changed: 2020-12-02
Basic data Employees D: 101 to 500 (2020-12-31)
  Currency USD
  Annual sales 23,911,000 (revenues, consolidated (2020) 2020-12-31)
  Profit -37,230,000 (2020-12-31)
  Cash 70,436,000 (2020-12-31)
    * Document for �About Section�: Pieris Pharmaceuticals, Inc.. (8/10/17). "Press Release: Pieris Pharmaceuticals Appoints Allan Reine, M.D., as Chief Financial Officer". Boston, MA.
Record changed: 2021-06-10


Picture [iito] Made Without Love 650x80px

More documents for Pieris (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC A October 650x80px

» top